Efficacy of cyclosporin A in rheumatoid arthritis: worldwide experience.
The effects of cyclosporin A (CyA) on the activity of RA have mainly been investigated in patients with active, refractory, long-term disease. The data obtained in these trials suggest that CyA is not only a symptomatic treatment for RA but can also be considered a DMARD. The potential benefits of CyA on one hand and its potential toxicity on the other indicate that a careful assessment should be made of its use in patients with early active RA.
Dougados
M
M
Department of Rheumatology, Réné Descartes University, Hôpital Cochin, Paris, France.
Torley
H
H
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D016572:Cyclosporine / Q000592:standards* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D015337:Multicenter Studies as Topic
D016572:Cyclosporine